---
schema_version: "secwatch.filing_event.v1"
accession: "0001410098-26-000020"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2026-05-14T11:34:46+00:00"
generated_at: "2026-05-14T11:40:59.694282+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CorMedix Q1 net revenue $127.4M, net income $38.6M; raises FY guidance

## Summary
- Q1 net revenue $127.4M, net income $38.6M, adjusted EBITDA $70.0M; EPS $0.48 basic/$0.43 diluted.
- DefenCath revenue $97.5M (incl. $9.0M favorable estimate change); Melinta portfolio $29.9M.
- Raises FY2026 guidance: net revenue $325-345M, adjusted EBITDA $115-135M.
- Positive Phase III topline for REZZAYO prophylaxis; sNDA submission H2 2026, potential launch 2027.
- Cash and investments $178.1M; TPN study trending to 2028, actions to accelerate enrollment.

## SEC filing metadata
- accession: 0001410098-26-000020
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2026-05-14T11:34:46+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000141009826000020/0001410098-26-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000141009826000020/crmd-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001410098-26-000020
- JSON: https://secwatch.observer/filing/0001410098-26-000020.json
- Plain text: https://secwatch.observer/filing/0001410098-26-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.